A history of treatments for myasthenia gravis

Seminars in Neurology

Volumn 24, Issue 1, 2004, Pages 5-16

  Keesey, John Carl ^a,b  

^a University of California ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

History; Myasthenia; Treatment

Indexed keywords

3 HYDROXYPHENYLDIMETHYLETHYL AMMONIUM BROMIDE; AMBENONIUM; ANTUITRIN; AZATHIOPRINE; BC 40; BC 47; BC 48; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CHORIONIC GONADOTROPIN; CORTICOTROPIN; CORTISONE; DISTIGMINE BROMIDE; DYFLOS; EDROPHONIUM BROMIDE; EDROPHONIUM CHLORIDE; EPHEDRINE; HEXAETHYLTETRAPHOSPHATE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; NEOSTIGMINE; OCTAMETHYL PYROPHOSPHORAMIDE; PHYSOSTIGMINE; POTASSIUM CHLORIDE; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; HEADACHE; HISTORY OF MEDICINE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION DISORDER; NEUROMUSCULAR SYNAPSE; ORGAN TRANSPLANTATION; PATHOGENESIS; PHLEBOTOMY; PRIORITY JOURNAL; RESPIRATORY CARE; REVIEW; THYMECTOMY;

CHOLINESTERASE INHIBITORS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; NEUROLOGY; THYMECTOMY;

EID: 3042690153     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829584     Document Type: Review

References (126)

1. Keesey J. Myasthenia Gravis, An Illustrated History. Roseville, CA: Publishers Design Group; 2002
2. Erb WH. Handbook of Electrotherapeutics. Pützel L, trans. New York: William Woods; 1883
3. Viets HR. A historical review of myasthenia gravis from 1672 to 1900. JAMA 1953;153:1273-1280
4. Goldflam S. Ueber einen scheinbar heilbaren bulbärparalytischen symptomencomplex mit betheiligung der extremitäten. Deutsche Z Nervenheilkunde 1893;4:312-352
5. Goldflam S. Weiteres uber die asthenische lahmung nebst einem obductionsbefund. Neurologishes Zentralblatt; 1902; 21:97-107, 490-496
6. Oppenheim H. Die Myasthenische Paralyse (Bulbärparalyse ohne anatomischen Befund. Berlin: S. Karger; 1901
7. Campbell H, Bramwell E. Myasthenia gravis. Brain 1900;23:277-336
8. Starr MA. Myasthenia gravis. J Nerv Ment Dis 1912;39:721-731
9. Oppenheim H. Weitere beitrag sur lehre von den acuten, night-eitrigen encephalitis und der poliencephalomyelitis. Deutsche Z Nervenheilkunde 1899;15:1-21
10. Weigert C. Pathologisch-anatomischer Beitrag zur Erb'schen Krankheit (Myasthenia gravis). Neurologisches Zentralblatt 1901;20:596-601
11. Schumacher CH, Roth P. Thymektomie bei einem Fall von Murbus Basedowi mit Myasthenia. Mitteilungen Grensgebeiten Medizin Chirurgie 1913;25:746-765
12. Keschner M, Strauss I. Myasthenia gravis. AMA Arch Neurol Psychiatry 1927;17:337-376
13. Kennedy FS, Moersch FP. Myasthenia gravis: a clinical review of eighty-seven cases observed between 1915 and early part of 1932. Can Med Assoc J 1935;37:216-223
14. Shaw LE. A case of bulbar paralysis without structural changes in the medulla. Brain 1890;13:96-99
15. Goerig M, Filos K, Ayisi KW. George Edward Fell and the development of respiratory machines. In: Atkinson RS, Boulton TB, eds. The History of Anesthesia. Park Ridge, NJ: Parthenon Publishing Group; 1987:386-393
16. Drinker P, McKhann CF. The use of a new apparatus for the prolonged administration of artificial respiration. JAMA 1929;92:1658-1660
17. Secher O. The polio epidemic in Copenhagen 1952. In: Atkinson RS, Boulton TB, eds. The History of Anesthesia. Park Ridge, NJ: Parthenon Publishing Group; 1987:425-432
18. Remen L. Zur pathogenese und therapie der myasthenia gravis pseudoparalytica. Deutsche Z Nervenheilkunde 1932; 128:66-78
19. Boothby WM, Adams M, Power MH, et al. Myasthenia gravis: second report on the effect of treatment with glycine. Mayo Clin Proc 1932;7:737-756
20. Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934;1:1200-1201
21. Keesey JC. Contemporary opinions about Mary Walker, a shy pioneer of therapeutic neurology. Neurology 1998;51:1433-1439
22. Everts WH. The treatment of myasthenia gravis by the oral administration of Prostigmin. Bull Neurol Inst 1935;4:523-530
23. Viets HR. Myasthenia gravis. JAMA 1945;127:1089-1096
24. Eaton LM. Care of the patient who has myasthenia gravis. Med Clin North Am 1947;31:907-923
25. Keesey JC. "Crisis" in myasthenia gravis: an historical perspective. Muscle Nerve 2002;26:1-3
26. Laurent LPE, Walther WW. The influence of large doses of potassium chloride on myasthenia gravis. Lancet 1935;1:1434-1435
27. Minot AS, Dodd K, Riven SS. Use of guanidine hydrochloride in treatment of myasthenia gravis. JAMA 1939;113:553-559
28. Blalock A, Mason MF, Morgan HJ, Riven SS. Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed. Ann Surg 1939;110:544-561
29. Blalock A, Harvey AM, Ford FR, Lilienthal JL. The treatment of myasthenia gravis by removal of the thymus gland: preliminary report. JAMA 1941;117:1529-1533
30. Clagett OT, Eaton LM. Surgical treatment of myasthenia gravis. J Thorac Surg 1947;16:62-80
31. Kirschner PA. Alfred Blalock and thymectomy for myasthenia gravis. Ann Thorac Surg 1987;43:348-349
32. Keynes G. The results of thymectomy in myasthenia gravis. BMJ 1949;1:611-616
33. Eaton LM, Clagett OT. Thymectomy in the treatment of myasthenia gravis. Results in seventy-two cases compared to one hundred and forty-two control cases. JAMA 1950;142:963-967
34. Eaton LM, Clagett OT. Present status of thymectomy in treatment of myasthenia gravis. Am J Med 1955;19:703-717
35. Givel JC. Historical review. In: Givel JC, ed. Surgery of the Thymus. Berlin: Springer-Verlag; 1990:1-9
36. Schwab RS, Leland CC. Sex and age in myasthenia gravis as critical factors in incidence and remission. JAMA 1953;153:1270-1280
37. Grob D. Myasthenia gravis, current status of pathogenesis, clinical manifestations, and management. J Chronic Dis 1958;8:536-566
38. Perlo VP, Poskanzer DC, Schwab RS, Viets HR, Osserman KE, Genkins G. Myasthenia gravis: evaluation of treatment in 1,355 patients. Neurology 1966;16:431-439
39. Bernatz PE in discussion following Buckingham JM, Howard FM, Bernatz PE, Payne WS, Harrison EG, O'Brien PC, Weiland LH. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg 1976;184:453-458
40. Kirschner PA. The history of surgery of the thymus gland. Chest Surg Clin N Am 2000;10:153-165
41. Osserman KE, Teng P, Kaplan LI. Studies in myasthenia gravis. Preliminary report on therapy with Mestinon bromide. JAMA 1954;155:961-965
42. Comroe JH, Todd J, Gammon GD, et al. The effect of diisopropyl- fluorophosphate (DFP) upon patients with myasthenia gravis. Am J Med Sci 1946;212:641-651
43. Westerberg MR, Luros JT. The clinical use of hexaethyl tetraphosphate in myasthenia gravis. Med Bull (Ann Arbor) 1948;14:15-17
44. Burgen ASV, Keel CA, McAlpine D. Tetra-ethylpyrophosphate in myasthenia gravis. Lancet 1948;1:519-521
45. Rider JA, Schulman S, Richter RB, Moeller HC, DuBois KP. Treatment of myasthenia gravis with octamethyl phyrophosphoramide. JAMA 1951;145:967-972
46. Artusio JF, Riker WF, Wescoe WC. Studies on the interrelationship of certain cholinergic compounds. IV. Anticurare action in anesthetized man. J Pharmacol Exp Ther 1950;100:227-237
47. MacFarlane DW, Pelikan We, Unna KR. Evaluation of curarizing drugs in man. V. Antagonism to curarizing effects of d-tubocurarine by neostigmine, m-hydroxy phenyltrimethylammonium and m-hydroxy phenylethyldimethylammonium. J Pharmacol Exp Ther 1950;100:382-392
48. Westerberg MR, Magee KR, Shideman FE. Effect of 3-hydroxy phenyldimethylethyl ammonium chloride (Tensilon) in myasthenia gravis. Med Bull (Ann Arbor) 1951;17:311-316
49. Westerberg MR, Magee KR, Shideman FE. Effect of Tensilon in myasthenia gravis. Neurology 1953;3:302-305
50. Tether JE. Mestinon in myasthenia gravis (preliminary report). Dis Nerv Syst 1954;15:227-231
51. Schwab RS, Timberlake WH. Pyridostigmin (Mestinon) in the treatment of myasthenia gravis. N Engl J Med 1954; 251:271-272
52. Westerberg MR, Magee KR. Mestinon in the treatment of myasthenia gravis. Neurology 1954;4:762-771
53. Schwab RS. WIN 8077 in the treatment of sixty myasthenia gravis patients, a twelve-month report. Am J Med 1955;19:734-736
54. Westerberg MR. Clinical evaluation of ambenonium (Mysuran) chloride. AMA Arch Neurol Psychiatry 1956; 75:91-94
55. Kraupp O, Stumpf C, Herzfeld E, Pillat B. Pharmakologische Eigenschaften einiger langwirksamer Cholinesterase-Hemmkörper aus der Reihe der Polymethylen-bis-(Carbaminoyl-m-Trimethylammoniumphenole). Arch Int Parmacodyn Ther 1955;102:281-303
56. Pateisky K, Herzfeld E, Stumpf C. Der Effekt von Polymethylen-bis-(N- methyl-m-trimethylammonium-phenolen) BC40, BC47, BC58 auf Cholinesteraseaktivität und Muskeltätigkeit bei Myasthenia gravis pseudparalytica. Wein KlinWochenschr 1957;69:2-7
57. Hoefer PFA, Aronow H, Rowland LP. Long-acting compounds, especially BC 51, in the treatment of myasthenia gravis. In: Viets HR, ed. Myasthenia Gravis. The Second International Symposium Proceedings. Springfield, IL: Charles C. Thomas; 1961:545-555
58. Schwarz H. Urecholine in myasthenia gravis. Can Med Assoc J 1955;72:346-351
59. Gottlieb B, Laurent LPE. Spironolactone in the treatment of myasthenia gravis. Lancet 1961;2:528-529
60. Satoyoshi E, Murakami K, Okazaki T. Triamterene in the treatment of myasthenia gravis. Lancet 1964;15:741-742
61. Somers JE, Irwin RL, Shy GM. The use of lycoramine derivatives in myasthenia gravis. Neurology 1963;13:543-553
62. Foldes FF, Foldes VM, McNall PG. The use of echothiophate in myasthenia gravis. Clin Pharmacol Ther 1966;7:620-630
63. Hofmann WW. Action of veratrine on human skeletal muscle with special reference to myasthenia gravis. Neurology 1958;8:417-432
64. Flacke W, Caviness VS, Samaha FG. Treatment of myasthenia gravis with germine diacetate. N Engl J Med 1966;275:1207-1214
65. Marsh DO. Adrenal therapy for neuromuscular disease including myasthenia gravis from 1896. N Y State J Med 1974;74:1974-1976
66. Simon HE. Myasthenia gravis, effect of treatment with anterior pituitary extract: preliminary report. JAMA 1935; 104:2065-2066
67. Schlezinger NS. Evaluation of therapy in myasthenia gravis. Arch Intern Med 1940;65:60-77
68. Torda C, Wolff HG. Effects of adrenocorticotrophic hormone on neuro-muscular function in patients with myasthenia gravis. Proc Soc Exp Biol Med 1949;71:432-435
69. Millikan CH, Eaton LM. Clinical evaluation of ACTH and cortisone in myasthenia gravis. Neurology 1951;1:145-152
70. Grob D, Harvey AM. Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis, and report on onset of myasthenia gravis during prolonged cortisone administration. Bull Johns Hopkins Hosp 1952;91:124-136
71. Freydberg LD. The place of corticotrophin in the treatment of myasthenia gravis. Ann Intern Med 1960;52:806-818
72. Schlezinger NS. Present status of therapy in myasthenia gravis. JAMA 1952;148:508-513
73. Osserman KE. Myasthenia Gravis. New York: Grune & Stratton; 1958:159
74. von Reis G, Liljestrand Å, Matell G. Results with ACTH and spironolactone in severe cases of myasthenia gravis. Acta Neurol Scand Suppl 1965;13:463-471
75. Simpson J. Myasthenia gravis: a new hypothesis. Scott Med J 1960;5:419-436
76. Osserman KE, Genkins G. Studies in myasthenia gravis. Short-term massive corticotrophin therapy. JAMA 1966; 198:699-702
77. Grob D, Namba T. Corticotrophin in generalized myasthenia gravis. Effect of short, intensive courses. JAMA 1966; 198:703-707
78. Thevènard A. Carotid sinus denervation in myasthenia gravis. In: Viets HR, ed. Myasthenia Gravis. The Second International Symposium Proceedings. Springfield, IL: Charles C Thomas; 1961:624-633
79. Kjaer M. Myasthenia gravis and myasthenic syndromes treated with prednisone. Acta Neurol Scand 1971;47:464-474
80. Warmolts JR, Engel WK. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med 1972;286:17-20
81. Jenkins RB. Treatment of myasthenia gravis with prednisone. Lancet 1972;1:765-767
82. Shy GM, Brendler S, Rabinovitch R, McEachern D. Effects of cortisone in certain neuromuscular disorders. JAMA 1950;144:1353-1358
83. Strauss AJL, Seegal BC, Hsu KC, Burkholder PM, Nastuk WL, Osserman KE. Immunofluorescence demonstration of a muscle binding, complement fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol Med 1960;105:184-191
84. Miller JFAP. Immunological function of the thymus. Lancet 1961;2:748-749
85. Wolf SM, Rowland LP, Schotland DL, McKinney AS, Hoefer PFA, Aranow H. Myasthenia as an autoimmune disease. Clinical aspects. Ann N Y Acad Sci 1966;135:517-535
86. Rowland LP. Immunosuppressive drugs in treatment of myasthenia gravis. Ann N Y Acad Sci 1971;183:351-357
87. Delwaide PJ, Salmon J, van Cauwenberger H. Premiers essais de traitement de la myasthenia par azathioprine. Acta Neurol Psychiatr Belg 1967;67:701-712
88. Guille-Minault C. Premiers essais de traitement de la myasthenia par azathioprine. Gaz Med Fr 1968;75:6545
89. Mertens HG, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol 1969;2:321-339
90. Hertel G, Mertens HG, Reuther P, Ricker K. The treatment of myasthenia gravis with azathioprine. In: Dau PC, ed. Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA: Houghton Mifflin; 1979:315-328
91. Matell G, Bergström K, Franksson C, et al. Effects of some immunosuppressive procedures on myasthenia gravis. Ann N Y Acad Sci 1976;274:659-676
92. Szobor A, Petrányi G. Immunosuppressive therapy of myasthenia gravis. Acta Med Acad Sci Hung 1970;27:397-411
93. Nouza K, Šmat V. The favourable effect of cyclophosphamide in myasthenia gravis. Rev Fr Etud Clin Biol 1968; 13:161-163
94. Perez MC, Buot WL, Mercado-Danguilan C, Bababaldo ZG, Renales LD. Stable remission in myasthenia gravis. Neurology 1981;31:32-37
95. Goulon M, Elkharrat D, Gajdos P, Lokiec F, Morel E. Preliminary results in myasthenia gravis treated with cyclosporin. Ann N Y Acad Sci 1987;505:857-860
96. Tindall RSA, Rollins JA, Phillips JT, Greelee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719-724
97. Nyberg-Hansen R, Gjerstad L. Myasthenia gravis treated with cyclosporin. Acta Neurol Scand 1988;77:307-313
98. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51:912-913
99. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-96
100. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-99
101. Riven SS, Mason MF. The treatment of myasthenia gravis. South Med J 1937;30:181-190
102. Aring CD. Treatment of myasthenia gravis with the Roentgen ray. Ohio State Med J 1943;39:241-244
103. Keynes G. Investigations into thymic disease and tumour formation. Br J Surg 1955;42:449-462
104. Grob D. Course and management of myasthenia gravis. JAMA 1953;153:529-532
105. Henson RA, Stern GA, Thompson VC. Thymectomy for myasthenia gravis. Brain 1965;88:11-28
106. Schwab RS. Evaluation of one hundred and thirty thymectomies. In: Viets HR, ed. Myasthenia Gravis. The Second International Symposium Proceedings. Springfield, IL: Charles C Thomas; 1961:597-601
107. Schulz MD, Schwab RS. Results of thymic (mediastinal) irradiation in patients with myasthenia gravis. Ann N Y Acad Sci 1971;183:303-307
108. Philllips TL, Buschke F. The role of radiation therapy in myasthenia gravis. Calif Med 1967;106:282-289
109. Currier RD, Routh A, Hickman BT, Douglas MA. Thymus irradiation for myasthenia gravis. Radiology 1983;146:199-201
110. Engel WK, Lichter AS, Dalakas M. Spenic and total-body irradiation treatment of myasthenia gravis. Ann N Y Acad Sci 1981;377:744-754
111. Durelli L, Ferrio MF, Urgesi A, Poccardi G, Ferrero B, Bergamini L. Total body irradiation for myasthenia gravis: a long-term follow-up. Neurology 1993;43:2215-2221
112. Stricker E, Thölen H, Massini MA, Stauf H. The effect of haemodialysis in myasthenia gravis. J Neurol Neurosurg Psychiatry 1960;23:291-294
113. Hedger RW, Davis FA, Schwartz FD, Ing TS. Improvement of myasthenia gravis by hemodialysis in a patient with chronic renal failure. Ann Intern Med 1971;75:749-752
114. Patten BM. A hypothesis to account for the Mary walker phenomenon. Ann Intern Med 1975;82:411-415
115. Lefvert AK, Matell G. Thoracic duct lymph drainage in myasthenia gravis: clinical effect and kinetic studies of the acetylcholine receptor antibody. In: Dau PC, ed. Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA: Houghton Mifflin; 1979:151-160
116. Tindall SC, Peters BH, Caverley JR, Sarles HE, Fish JC. Thoracic duct lymphocyte depletion in myasthenia gravis. Arch Neurol 1973;29:202-203
117. Bergstrom K, Franksson C, Matell G, et al. Drainage of thoracic duct lymph in twelve patients with myasthenia gravis. Eur Neurol 1975;13:19-30
118. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Neurology 1976;26:1054-1059
119. Pinching AF, Peters DK, Newsom-Davis J. Remission of myasthenia gravis following plasma exchange. Lancet 1976; 2:1373-1376
120. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977;297:1134-1140
121. Pirofsky B, Reid RH, Bardana EJ, Baker RL. Antithymocyte antiserum therapy in myasthenia gravis. Postgrad Med J 1976;52(suppl 5):112-117
122. Pirofsky B, Reid RH, Bardana EJ, Baker RL. Myasthenia gravis treated with purified antithymocyte antiserum. Neurology 1979;29:112-116
123. Leövey A, Szobor A, Szegedi G, Szathmáry I, Petrányi G. Myasthenia gravis: ALG treatment of seriously ill patients. Eur Neurol 1975;13:422-432
124. Genkins G, Paptestas AE, Kornfeld P, Horowitz SH. Studies in myasthenia gravis: staging and gamma globulin. In: Dau PC, ed. Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA: Houghton Mifflin; 1979:144-150
125. Gajdos P, Outin H, Elkharrat D, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1:406-407
126. Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146:1365-1368